Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
about
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment.Prevalence and microbiological characteristics of clinically infected foot-ulcers in patients with rheumatoid arthritis: a retrospective exploratory studyBoth anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice.Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.Adverse effects of golimumab in the treatment of rheumatologic diseases.Rheumatoid arthritis is caused by a Proteus urinary tract infection.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.Vaccination of patients with autoimmune inflammatory rheumatic diseases.Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Cutaneous side effects of TNF-alpha inhibitors.Nebenwirkungen von TNF-alpha-Inhibitoren am Hautorgan.Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.Psoriatic arthritis treatment and the risk of herpes zoster.Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.Injectable tumor necrosis factor α inhibitors and outpatient antimicrobial use in children with rheumatic diseases: analyses of prescription claims from a pharmacy benefit manager database.Serious infections among a large cohort of subjects with systemically treated psoriasis.Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.Rheumatoid arthritis - an update for general dental practitioners.Etanercept in the treatment of rheumatoid arthritis.
P2860
Q28074148-A683674B-6D75-4EFD-AA41-6622EBB85C26Q30725001-EC18B560-40BB-4100-AA92-4DDAC5A355CAQ35686918-42A26312-1E24-454D-82C8-865119275096Q35838797-3FF26D47-5505-4B28-BF69-B995F02334F1Q35957200-F340AC00-77E5-4E1F-82C3-945ACD039D4FQ36298389-48C27167-43CB-4B7F-A55A-36EAF8CA1AF7Q37330765-94EEC21A-0883-49D2-94DC-EF90E70D1B40Q37484842-84B5BE61-920C-45A6-BF85-0487968677C4Q37576833-21679D83-9A70-4C63-BED4-141DCD0EBA6EQ37616969-62D4B67A-463A-4615-8A97-E868495BA267Q37714705-68B6CEAD-833D-4566-9409-B796D8BDBD7AQ37729543-1C0CFB82-F0FD-40E6-8947-5F3E41D41E9FQ38132273-B3F7489F-DB61-454F-98C7-48B0A652D4C6Q38132898-A6BDF082-B059-4B4C-8308-3A8FB7424A44Q38176745-2B602D81-58EF-47B8-AF3C-261EA7419DD4Q38192553-7BE1B1D5-ECDD-42AF-BDBD-95689EF10754Q38197448-724A49CC-EBC5-4001-9A73-624E561124B1Q38235809-D110886C-64DE-4C8B-9EBF-F49E1D71848CQ38285275-224F4F59-E22F-480A-A1DB-B2146D2EE81AQ38418892-EB7E5F9B-CF9D-4FBE-9F5E-55378C2FFC20Q38458992-039A34FC-1D3B-405E-8CDA-26D9CCD445E2Q38611360-0F3731D5-8B17-4555-92CB-3F0CF87CB9D8Q38668352-4B6F514A-EB0B-48F9-867B-62DC4A3289B9Q38837769-6ED43D49-5179-4597-8B1B-999AF5723101Q38933554-F6410AF1-D1F2-4C0E-8B78-99A673CC3428Q39158058-160B7F7B-1890-4B72-8E17-C162A1B3B4FFQ40355795-6C9CF670-80D6-4E07-88EC-8DE99508974CQ40598586-F915B4A4-07C0-4910-BA7E-F905C0DA2873Q41713104-0D88B10E-DC32-4544-B290-C8B61ACE6727Q41920067-2AFEEC1C-F72F-4B49-A13B-2A5826B1488EQ44278805-7370CAA3-240A-4623-9ADC-D8A931D11F5AQ45093232-064F3EEB-D907-44C0-98EC-8AD54B7829F0Q46008043-533F27FE-8BD3-4C93-BE75-EE7CD951FF12Q46731189-04098F1A-078C-42DD-91FF-18A476CCE735Q47831413-8C2810AD-4F3D-4721-B9BD-3162ADA0157FQ52810344-511F573F-980A-47F6-93F0-85BAB903707AQ52841141-4CF296E5-90BF-4B46-B56E-F957E7ED0F06
P2860
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Risk of skin and soft tissue i ...... eumatology Biologics Register.
@ast
Risk of skin and soft tissue i ...... eumatology Biologics Register.
@en
type
label
Risk of skin and soft tissue i ...... eumatology Biologics Register.
@ast
Risk of skin and soft tissue i ...... eumatology Biologics Register.
@en
prefLabel
Risk of skin and soft tissue i ...... eumatology Biologics Register.
@ast
Risk of skin and soft tissue i ...... eumatology Biologics Register.
@en
P2093
P2860
P50
P1476
Risk of skin and soft tissue i ...... eumatology Biologics Register.
@en
P2093
Alison Moseley
Andrew P Ustianowski
Deborah Pm Symmons
Kath D Watson
Kimme L Hyrich
Louise K Mercer
Matthew Helbert
P2860
P304
P356
10.1136/ANNRHEUMDIS-2011-201108
P407
P577
2012-04-24T00:00:00Z